Nerve Growth Factor
Dysphagia
The Third Affiliated hospital of Zhejiang Chinese Medical UniversityPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Dysphagia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Modafinil University of Arkansas | Phase 2 | B |
Carboplatin Swedish Orphan Biovitrum | Phase 2 | B |
Manuka Honey In Liquid Form Radiation Therapy Oncology Group | Phase 2 | B |
Palifermin Swedish Orphan Biovitrum | Phase 2 | B |
Nicergoline Phramongkutklao College of Medicine and Hospital | Phase 3 | B |
View all 15 →
Same molecule, other indications
Nerve Growth Factor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →